Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/12941
DC FieldValueLanguage
dc.contributor.authorGrozdanova, Aleksandraen_US
dc.contributor.authorHalimi Vesaen_US
dc.contributor.authorZaheer-Ud-Din Babaren_US
dc.contributor.authorArmond Dacien_US
dc.contributor.authorKaterina Ancevska Netkovskaen_US
dc.contributor.authorLjubica Suturkovaen_US
dc.date.accessioned2021-05-31T12:21:17Z-
dc.date.available2021-05-31T12:21:17Z-
dc.date.issued2020-08-03-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12941-
dc.language.isoenen_US
dc.publisherInt. J. Environ. Res. Public Healthen_US
dc.relation.ispartofInt. J. Environ. Res. Public Healthen_US
dc.subjectbiosimilars; clinical practice; interchangeability; extrapolation; pharmacovigilance; regulatory; knowledge; confidence; educationen_US
dc.titleClinical and Regulatory Concerns of Biosimilars: A Review of Literatureen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/ijerph17165800-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Pharmacy-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Files in This Item:
File Description SizeFormat 
ijerph-17-05800 (3).pdf476.13 kBAdobe PDFView/Open
Show simple item record

Page view(s)

56
checked on May 6, 2024

Download(s)

62
checked on May 6, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.